News | February 21, 2022
Corbevax receives EUA for 12-18 age group
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The recommendation has been sent to the DCGI for approval
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Pfizer and Moderna are also working on vaccines that target the Omicron variant
The recommendations have been sent to the Drugs Controller General of India (DCGI) for the final approval
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
The vaccines are currently only authorised for emergency use in the country
However, these won’t be available at the nearest chemist store soon
Subscribe To Our Newsletter & Stay Updated
